Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-07-18 pm EDT After market 07:59:49 pm
848.9 USD -6.26% Intraday chart for Eli Lilly and Company 854.8 +0.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Health Care Drops as Novo Nordisk, Eli Lilly Slide - Health Care Roundup DJ
Wall Street falls as investors look beyond megacap shares RE
Global markets live: Adidas, TSMC, Vale, HSBC, J&J... Our Logo
Stocks to watch as Biden, Trump vie for presidency RE
TD Cowen Raises Price Target on Eli Lilly to $1,050 From $850 MT
Earnings reports take center stage as tech stocks tumble Our Logo
Wall Street set to fall as megacap chip, tech stocks tumble RE
ANALYST RECOMMENDATIONS : American Airlines, Chevron, UnitedHealth, Bank of America, Eli Lilly... Our Logo
Roche reports positive early results in obesity drug trial RE
Aclaris Therapeutics Sells Olumiant Royalties, Milestone Payments From Eli Lilly MT
Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793 MT
Novo owner backs Swiss biotech Asceneuron in $100 million round RE
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market RE
Ozempic linked with lower dementia risk, nicotine use, British study finds RE
EU Drug Regulator Issues New Safety Measures for GLP-1 Drugs Amid Aspiration Risk Concerns MT
UBS Raises Price Target on Eli Lilly to $1,100 From $910, Maintains Buy Rating MT
Patients on weight-loss drugs should inform doctor before surgery, EU regulator says RE
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup DJ
Pfizer moves forward with once-daily weight loss drug RE
JPMorgan Adjusts Price Target on Eli Lilly and Co. to $1,000 From $900, Maintains Overweight Rating MT
Morgan Stanley Adjusts Price Target on Eli Lilly and Co. to $1,083 From $1,023, Maintains Overweight Rating MT
Berenberg Adjusts Price Target on Eli Lilly & Co. to $1,000 From $850, Maintains Buy Rating MT
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices RE
SANDERS SAYS HE IS CURRENTLY FOCUSED ON NOVO NORDISK BUT WILL 'C… RE
Eli Lilly Names Gordon Brooks Interim Chief Financial Officer DJ
Chart Eli Lilly and Company
More charts
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
848.9 USD
Average target price
901.5 USD
Spread / Average Target
+6.19%
Consensus
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. News Eli Lilly and Company
  5. Sector Update: Health Care Stocks Decline Tuesday Afternoon